Cytogenetic evaluation of mesenchymal stem/stromal cells from patients with myelodysplastic syndromes at different time-points during ex vivo expansion

Leukemia Research

Volumn 43, Issue , 2016, Pages 24-32

  Kouvidi, Elisavet ^a   Stratigi, Aikaterini ^a   Batsali, Aristea ^a   Mavroudi, Irene ^a   Mastrodemou, Semeli ^a   Ximeri, Maria ^a   Papadaki, Helen A ^a   Pontikoglou, Charalampos G ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

Cytogenetic abnormalities; FISH; G banding; Mesenchymal stem cells; Myelodysplastic syndromes

Indexed keywords

ADULT; AGED; ARTICLE; CELL EXPANSION; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME G BAND; CLINICAL ARTICLE; CLONAL VARIATION; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; MALE; MESENCHYMAL STEM CELL; MESENCHYMAL STROMA CELL; MIDDLE AGED; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; TRISOMY; TRISOMY 5; TRISOMY 7; VERY ELDERLY; CHROMOSOME ABERRATION; CHROMOSOME BANDING PATTERN; CLINICAL TRIAL; GENETICS; GENOMIC INSTABILITY; HUMAN CHROMOSOME; PATHOLOGY;

AGED; AGED, 80 AND OVER; CELL PROLIFERATION; CHROMOSOME ABERRATIONS; CHROMOSOME BANDING; CHROMOSOMES, HUMAN; FEMALE; GENOMIC INSTABILITY; HUMANS; MALE; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES;

EID: 84959377819     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2016.02.007     Document Type: Article

References (42)

1. Tefferi A., Vardiman J.W. Myelodysplastic syndromes. N. Engl. J. Med. 2009, 361(19):1872-1885.
2. Bulycheva E., Rauner M., Medyouf H., Theurl I., Bornhauser M., Hofbauer L.C., et al. Myelodysplasia is in the niche: novel concepts and emerging therapies. Leukemia 2015, 29(2):259-268.
3. Medyouf H., Mossner M., Jann J.C., Nolte F., Raffel S., Herrmann C., et al. Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit. Cell Stem Cell 2014, 14(6):824-837.
4. Raaijmakers M.H., Mukherjee S., Guo S., Zhang S., Kobayashi T., Schoonmaker J.A., et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 2010, 464(7290):852-857.
5. Klaus M., Stavroulaki E., Kastrinaki M.C., Fragioudaki P., Giannikou K., Psyllaki M., et al. Reserves, functional, immunoregulatory, and cytogenetic properties of bone marrow mesenchymal stem cells in patients with myelodysplastic syndromes. Stem Cells Dev. 2010, 19(7):1043-1054.
6. Aanei C.M., Flandrin P., Eloae F.Z., Carasevici E., Guyotat D., Wattel E., et al. Intrinsic growth deficiencies of mesenchymal stromal cells in myelodysplastic syndromes. Stem Cells Dev. 2012, 21(10):1604-1615.
7. Zhao Z.G., Xu W., Yu H.P., Fang B.L., Wu S.H., Li F., et al. Functional characteristics of mesenchymal stem cells derived from bone marrow of patients with myelodysplastic syndromes. Cancer Lett. 2012, 317(2):136-143.
8. Kastrinaki M.C., Pavlaki K., Batsali A.K., Kouvidi E., Mavroudi I., Pontikoglou C., et al. Mesenchymal stem cells in immune-mediated bone marrow failure syndromes. Clin. Dev. Immunol. 2013, 2013:265608.
9. Geyh S., Oz S., Cadeddu R.P., Frobel J., Bruckner B., Kundgen A., et al. Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells. Leukemia 2013, 27(9):1841-1851.
10. List A.F., Vardiman J., Issa J.P., DeWitte T.M. Myelodysplastic syndromes. Hematol. Am. Soc. Hematol. Educ. Program 2004, 297-317.
11. Haase D., Germing U., Schanz J., Pfeilstocker M., Nosslinger T., Hildebrandt B., et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007, 110(13):4385-4395.
12. Soenen-Cornu V., Tourino C., Bonnet M.L., Guillier M., Flamant S., Kotb R., et al. Mesenchymal cells generated from patients with myelodysplastic syndromes are devoid of chromosomal clonal markers and support short- and long-term hematopoiesis in vitro. Oncogene 2005, 24(15):2441-2448.
13. Ramakrishnan A., Awaya N., Bryant E., Torok-Storb B. The stromal component of the marrow microenvironment is not derived from the malignant clone in MDS. Blood 2006, 108(2):772-773.
14. Han Q., Sun Z., Liu L., Chen B., Cao Y., Li K., et al. Impairment in immuno-modulatory function of Flk1(+)CD31(-)CD34(-) MSCs from MDS-RA patients. Leuk. Res. 2007, 31(11):1469-1478.
15. Flores-Figueroa E., Arana-Trejo R.M., Gutierrez-Espindola G., Perez-Cabrera A., Mayani H. Mesenchymal stem cells in myelodysplastic syndromes: phenotypic and cytogenetic characterization. Leuk. Res. 2005, 29(2):215-224.
16. Blau O., Hofmann W.K., Baldus C.D., Thiel G., Serbent V., Schumann E., et al. Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia. Exp. Hematol. 2007, 35(2):221-229.
17. Lopez-Villar O., Garcia J.L., Sanchez-Guijo F.M., Robledo C., Villaron E.M., Hernandez-Campo P., et al. Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q- syndrome. Leukemia 2009, 23(4):664-672.
18. WHO Classification of Tumours: Pathology and Genetics of Haematopoietic and Lymphoid Tissues 2008, IARC Press, Lyon ed.
19. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89(6):2079-2088.
20. Kastrinaki M.C., Sidiropoulos P., Roche S., Ringe J., Lehmann S., Kritikos H., et al. Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis. Ann. Rheum. Dis. 2008, 67(6):741-749.
21. Pavlaki K., Pontikoglou C.G., Demetriadou A., Batsali A.K., Damianaki A., Simantirakis E., et al. Impaired proliferative potential of bone marrow mesenchymal stromal cells in patients with myelodysplastic syndromes is associated with abnormal WNT signaling pathway. Stem Cells Dev. 2014, 23(14):1568-1581.
22. Cristofalo V.J., Allen R.G., Pignolo R.J., Martin B.G., Beck J.C. Relationship between donor age and the replicative lifespan of human cells in culture: a reevaluation. Proc. Natl. Acad. Sci. U. S. A. 1998, 95(18):10614-10619.
23. ISCN An International System for Human Cytogenetic Nomenclature 2013, ISCN, Basel, Switzerland: Karger.
24. Raaijmakers M.H. Niche contributions to oncogenesis: emerging concepts and implications for the hematopoietic system. Haematologica 2011, 96(7):1041-1048.
25. Raaijmakers M.H. Disease progression in myelodysplastic syndromes: do mesenchymal cells pave the way?. Cell Stem Cell 2014, 14(6):695-697.
26. Santamaria C., Muntion S., Roson B., Blanco B., Lopez-Villar O., Carrancio S., et al. Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients. Haematologica 2012, 97(8):1218-1224.
27. Oliveira F.M., Lucena-Araujo A.R., Favarin M.C., Palma P.V., Rego E.M., Falcao R.P., et al. Differential expression of AURKA and AURKB genes in bone marrow stromal mesenchymal cells of myelodysplastic syndrome: correlation with G-banding analysis and FISH. Exp. Hematol. 2013, 41(2):198-208.
28. Tarte K., Gaillard J., Lataillade J.J., Fouillard L., Becker M., Mossafa H., et al. Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood 2010, 115(8):1549-1553.
29. Ozisik Y.Y., Morgan R., Peier A., Meloni A.M., Sandberg A.A. Trisomy 5 in long-term cultures from bone marrow of patients with solid tumors. Cancer Genet. Cytogenet. 1994, 78(2):207-209.
30. Kim J.A., Im K.O., Park S.N., Kwon J.S., Kim S.Y., Oh K., et al. Cytogenetic heterogeneity and their serial dynamic changes during acquisition of cytogenetic aberrations in cultured mesenchymal stem cells. Mutat. Res. 2015, 777:60-68.
31. Broberg K., Toksvig-Larsen S., Lindstrand A., Mertens F. Trisomy 7 accumulates with age in solid tumors and non-neoplastic synovia. Genes. Chromosomes Cancer 2001, 30(3):310-315.
32. Johansson B., Heim S., Mandahl N., Mertens F., Mitelman F. Trisomy 7 in nonneoplastic cells. Genes Chromosomes Cancer 1993, 6(4):199-205.
33. Kinne R.W., Kunisch E., Beensen V., Zimmermann T., Emmrich F., Petrow P., et al. Synovial fibroblasts and synovial macrophages from patients with rheumatoid arthritis and other inflammatory joint diseases show chromosomal aberrations. Genes Chromosomes Cancer 2003, 38(1):53-67.
34. Blau O., Baldus C.D., Hofmann W.K., Thiel G., Nolte F., Burmeister T., et al. Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts. Blood 2011, 118(20):5583-5592.
35. Song L.X., Guo J., He Q., Yang L.P., Gu S.C., Zhang Z., et al. [Study on phenotypic and cytogenetic characteristics of bone marrow mesenchymal stem cells in myelodysplastic syndromes]. Zhonghua Xue Ye Xue Za Zhi 2013, 34(2):127-132.
36. Kim Y., Jekarl D.W., Kim J., Kwon A., Choi H., Lee S., et al. Genetic and epigenetic alterations of bone marrow stromal cells in myelodysplastic syndrome and acute myeloid leukemia patients. Stem Cell Res. 2015, 14(2):177-184.
37. Vallespi T., Imbert M., Mecucci C., Preudhomme C., Diagnosis Fenaux P. classification, and cytogenetics of myelodysplastic syndromes. Haematologica 1998, 83(3):258-275.
38. Estrada L., Torres A., Garcia-Casado J., Prats-Boluda G., Jane R. Characterization of laplacian surface electromyographic signals during isometric contraction in biceps brachii. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2013, 2013:535-538.
39. Barkholt L., Flory E., Jekerle V., Lucas-Samuel S., Ahnert P., Bisset L., et al. Risk of tumorigenicity in mesenchymal stromal cell-based therapies-bridging scientific observations and regulatory viewpoints. Cytotherapy 2013, 15(7):753-759.
40. Capelli C., Pedrini O., Cassina G., Spinelli O., Salmoiraghi S., Golay J., et al. Frequent occurrence of non-malignant genetic alterations in clinical grade mesenchymal stromal cells expanded for cell therapy protocols. Haematologica 2014, 99(6):e94-e97.
41. Flores-Figueroa E., Montesinos J.J., Flores-Guzman P., Gutierrez-Espindola G., Arana-Trejo R.M., Castillo-Medina S., et al. Functional analysis of myelodysplastic syndromes-derived mesenchymal stem cells. Leuk. Res. 2008, 32(9):1407-1416.
42. Xiong H., Yang X.Y., Han J., Wang Q., Zou Z.L. Cytokine expression patterns and mesenchymal stem cell karyotypes from the bone marrow microenvironment of patients with myelodysplastic syndromes. Braz. J. Med. Biol. Res. 2015, 48(3):207-213.